XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Cash, Cash Equivalents and Investments
9 Months Ended
Sep. 30, 2023
Cash, Cash Equivalents and Investments  
Cash, Cash Equivalents and Investments

Note 3 - Cash, Cash Equivalents and Investments

The following tables summarize our cash, cash equivalents, marketable securities, and available-for-sale investments at September 30, 2023 and December 31, 2022 (in thousands):

As of September 30, 2023

    

  

Gross

  

Gross

  

  

 

Cash and

  

  

  

Amortized

Unrealized

Unrealized

 

Cash

Marketable

Short-Term

Long-Term

Cost

Gains

Losses

Fair Value

 

Equivalents

Securities

Investments

Investments

Cash

$

224,437

$

$

$

224,437

$

224,437

$

$

$

Level 1:

 

  

 

  

 

  

 

  

 

  

 

  

 

Money market funds

 

25,292

 

 

25,292

 

25,292

 

 

Agency bonds

 

170,838

17

 

(347)

 

170,508

 

33,500

 

 

137,008

Treasury bills

133,779

20

133,799

122,813

10,986

Marketable securities

90,000

(21,150)

68,850

 

 

68,850

 

Subtotal

 

419,909

37

 

(21,497)

 

398,449

181,605

68,850

147,994

Level 2:

Term deposits

203,205

203,205

203,205

Corporate bonds

121,071

8

(559)

120,520

120,520

U.S. government

176,371

(700)

175,671

175,671

Treasury Inflation-Protected Securities

2,606

(11)

2,595

2,595

Commercial paper

65,703

65,703

65,703

Subtotal

568,956

8

(1,270)

567,694

567,694

Total

$

1,213,302

$

45

$

(22,767)

$

1,190,580

$

406,042

$

68,850

$

715,688

$

As of September 30, 2023, we had $390.4 million of available-for-sale investments with unrealized losses. Of the $390.4 million of available-for-sale investments with unrealized losses, $27.0 million has been in a continuous unrealized loss position for twelve months or longer, with total gross unrealized losses of $0.3 million. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases.

During the year ended December 31, 2021, we acquired 9.0 million shares of common stock of Cellebrite DI Ltd (“CLBT”) with a fair value of $90.0 million. The CLBT common stock is recorded as marketable securities in the accompanying condensed consolidated balance sheets and its fair value is adjusted every reporting period. Changes in fair value are recorded in the condensed consolidated statement of operations as unrealized gain or (loss) on marketable securities, which is included in interest and other income (loss), net. During the three and nine months ended September 30, 2023, we recorded an unrealized gain on marketable securities of $4.1 million and $29.6 million, respectively, relating to CLBT.

As of December 31, 2022

    

  

Gross

  

Gross

  

  

 

Cash and

  

  

  

Amortized

Unrealized

Unrealized

 

Cash

Marketable

Short-Term

Long-Term

Cost

Gains

Losses

Fair Value

 

Equivalents

Securities

Investments

Investments

Cash

$

143,744

$

$

$

143,744

$

143,744

$

$

$

Level 1:

 

  

 

  

 

  

 

  

 

  

 

  

 

Money market funds

 

2,669

 

 

2,669

 

2,669

 

 

Agency bonds

 

164,486

6

 

(263)

 

164,229

 

 

 

69,862

94,367

Treasury bills

121,650

18

(3)

121,665

113,100

8,565

Marketable securities

90,000

(50,760)

39,240

 

 

39,240

 

Subtotal

 

378,805

24

 

(51,026)

 

327,803

115,769

39,240

78,427

94,367

Level 2:

State and municipal obligations

4,980

(33)

4,947

4,947

Certificate of deposits

5,002

5,002

5,002

Term deposits

200,000

200,000

25,000

175,000

Corporate bonds

257,422

33

(1,159)

256,296

28,883

168,074

59,339

U.S. government

30,525

(159)

30,366

30,366

Treasury Inflation-Protected Securities

2,503

(2)

2,501

2,501

Commercial paper

160,241

160,241

40,288

119,953

Subtotal

660,673

33

(1,353)

659,353

94,171

503,342

61,840

Total

$

1,183,222

$

57

$

(52,379)

$

1,130,900

$

353,684

$

39,240

$

581,769

$

156,207